High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study

2017 ◽  
Vol 25 (2) ◽  
pp. 141-145 ◽  
Author(s):  
Tsukasa Nishioka ◽  
Norio Yoshimura ◽  
Hidetaka Ushigome ◽  
Yoshihiko Watarai ◽  
Kenji Nishimura ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Multicenter Study ◽  
Calcineurin Inhibitor ◽  
High Dose

A Japanese Multicenter Study of High-Dose Mizoribine Combined with Cyclosporine, Corticosteroid and Basiliximab in Renal Transplantation

2012 ◽  
Vol 94 (10S) ◽  
pp. 962
Author(s):  
Y. Oshiro ◽  
K. Nakagawa ◽  
K. Hoshinaga ◽  
A. Aikawa ◽  
S. Shishido ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Multicenter Study ◽  
High Dose

scholarly journals Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis

2017 ◽  
Vol 20 ◽  
pp. 168 ◽  
Author(s):  
Wang Xin ◽  
Yang Hui ◽  
Zhang Xiaodong ◽  
Cui Xiangli ◽  
Wang Shihui ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Acute Rejection ◽  
Low Dose ◽  
Opportunistic Infections ◽  
Meta Analysis ◽  
High Dose ◽  
Renal Transplant Recipients ◽  
Significant Difference ◽  
Allograft Loss ◽  
Cmv Disease

Objectives: Valganciclovir 900 mg/day is approved for cytomegalovirus (CMV) prophylaxis, but 450 mg/day is seems also effective. We systematically reviewed the efficacy and safety of low-dose versus high-dose valganciclovir prophylaxis in renal transplantation recipients. Methods: An electronic search was conducted up to November 29, 2016. The primary outcomes were incidences of CMV, CMV disease, mortality and opportunistic infection. The second outcomes were acute rejection, allograft loss, adverse drug reaction (ADR). Results: 7 cohort studies, all with high quality involving (1431 patients) were included. There was no significant difference of the incidence of following CMV disease (1271 patients, odds ratio [OR] 0.74, 95% confidence interval [CI], 0.38-1.43, p=0.36), acute rejection (1343 patients, OR 0.77, 95%CI 0.53-1.14, p=0.19), allograft loss (1271 patients, OR 0.64, 95%CI 0.31-1.35, p=0.24), mortality (1271 patients, OR 0.55, 95%CI 0.20-1.47, p=0.23) and opportunistic infections (OI) (985 patients, OR 0.76, 95%CI 0.52-1.10, p=0.14) between the low-dose and the high-dose valganciclovir  prophylaxis. And no significant difference was observed for premature valganciclovir discontinuation (1010 patients, OR 0.81, 95%CI 0.52-1.25, p=0.33) and the incidence of leukopenia (1082 patients, OR 0.65, 95%CI 0.34-1.22, p=0.18) between the two regimens. Conclusion: 450 mg and 900 mg doses of valganciclovir are equipotent for CMV universal prophylaxis. CMV 450 mg prophylaxis should be used for renal transplant recipients. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus

2010 ◽  
Vol 25 (6) ◽  
pp. 898-904 ◽  
Author(s):  
Clifford D. Miles ◽  
Jill Y. Skorupa ◽  
John P. Sandoz ◽  
Theodore H. Rigley ◽  
Kathleen J. Nielsen ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplantation ◽  
Low Dose ◽  
High Dose

High Rejection Rate during Calcineurin Inhibitor-Free and Early Steroid Withdrawal Immunosuppression in Renal Transplantation

2006 ◽  
Vol 82 (9) ◽  
pp. 1221-1223 ◽  
Author(s):  
Marielle A. C. J. Gelens ◽  
Maarten H. L. Christiaans ◽  
Ernst L. W. van Heurn ◽  
Ella P. M. van den Berg-Loonen ◽  
Carine J. Peutz-Kootstra ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Calcineurin Inhibitor ◽  
Rejection Rate ◽  
Steroid Withdrawal ◽  
High Rejection Rate ◽  
High Rejection

scholarly journals 1214P High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20

2021 ◽  
Vol 32 ◽  
pp. S966
Author(s):  
F. Zwierenga ◽  
B.A.M.H. van Veggel ◽  
L.E.L. Hendriks ◽  
T.J.N. Hiltermann ◽  
B.I. Hiddinga ◽  
...  
Keyword(s):  
Phase Ii ◽  
Multicenter Study ◽  
High Dose ◽  
Advanced Stage ◽  
Exon 20
Sign in / Sign up

Export Citation Format

Share Document